Blurbs

Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Arcellx Inc (ACLX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NeoGenomics (NEOResearch Report) and Arcellx Inc (ACLXResearch Report) with bullish sentiments.

NeoGenomics (NEO)

In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on NeoGenomics, with a price target of $20.00. The company’s shares closed last Monday at $17.79, close to its 52-week low of $13.90.

According to TipRanks.com, Souda has 0 stars on 0-5 stars ranking scale with an average return of -5.6% and a 37.2% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NeoGenomics with a $23.00 average price target, representing a 30.6% upside. In a report released today, Needham also maintained a Buy rating on the stock with a $19.00 price target.

See the top stocks recommended by analysts >>

Arcellx Inc (ACLX)

In a report released today, Daina Graybosch from Leerink Partners maintained a Buy rating on Arcellx Inc, with a price target of $44.00. The company’s shares closed last Monday at $15.34.

According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of -13.8% and a 33.6% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Werewolf Therapeutics, Century Therapeutics, and Nektar Therapeutics.

Currently, the analyst consensus on Arcellx Inc is a Strong Buy with an average price target of $31.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NEO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos